NMDP BioTherapies℠

46 articles about NMDP BioTherapies℠

• NMDP BioTherapies Introduces Enhanced Cellular Materials for Allogeneic Cell Therapy Development

  4/16/2024

  NMDP BioTherapies ℠, formerly Be The Match BioTherapies unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings.

• NMDP BioTherapies Appoints New President to Lead Next Phase in Life-Saving Therapy Development

  1/30/2024

  NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president, leading the organization into its promising future phase.

• Be The Match BioTherapies® and Cryoport Partner to Accelerate the Development of Cell and Gene Therapies

  10/9/2023

  Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Cryoport, a leading global provider of innovative products and services to the fast-growing cell & gene therapy industry enabling the future of medicine for a new era of life sciences, announced a new strategic partnership.

• Ossium Health® and Be The Match® Unveil Partnership to Increase Bone Marrow Transplant Accessibility and Treatment Efficiency

  8/31/2023

  Ossium Health and the National Marrow Donor Program® /Be The Match®, a global leader working to save lives through cellular therapy, announced their partnership to expand access to vital bone marrow and accelerate the industry’s ability to make bone marrow transplants accessible at scale.

• Be The Match BioTherapies® Marks Cord Blood Awareness Month with the Announcement of the Cord Blood Bank Alliance

  7/10/2023

  In anticipation of Cord Blood Awareness Month this July, Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, announced the formation of the Be The Match BioTherapies Cord Blood Bank Alliance.

• Phase III Clinical Trial Published in New England Journal Of Medicine Identifies New Standards for Prevention of Graft Versus Host Disease Following Transplant

  6/22/2023

  Results of a Phase III randomized clinical trial published in the New England Journal of Medicine indicates that a new strategy for prevention of graft versus host disease for blood cancer patients receiving allogeneic hematopoietic cell transplantation from well-matched donors significantly improves GVHD-free/relapse -free survival.

• Be The Match BioTherapies® To Provide Robust Cell Therapy Infrastructure to Support Garuda Therapeutics’ Potentially Ground-Breaking Off-The-Shelf Cell Therapies

  5/24/2023

  Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, announced a working partnership with Garuda Therapeutics, a company working to create off-the-shelf, durable blood stem cell-based cellular therapies.

• The National Marrow Donor Program® (NMDP)/Be The Match® and Be The Match BioTherapies® Mark Clinical Trials Day With New Resources and Services for Patients, Researchers, and Industry Sponsors

  5/17/2023

  The National Marrow Donor Program® /Be The Match® and Be The Match BioTherapies® launched a new web resource page and free white paper, “Paving the way to successful cell therapy clinical trials with a comprehensive approach and patient support,” to mark Clinical Trials Day 2023.

• Results of Pre-MEASURE Study By NMDP/Be The Match, CIBMTR, and the NHLBI Published in JAMA

  3/7/2023

  The National Marrow Donor Program® /Be The Match® in partnership with CIBMTR® and the National Institute of Health’s National Heart, Lung, and Blood Institute announced that the Journal of the American Medical Association published findings from the Pre-MEASURE study.

• Be The Match BioTherapies® Launches CIBMTR® CRO Services for Cell and Gene Therapy

  1/17/2023

  Be The Match BioTherapies® announced it is offering CIBMTR® Clinical Research Organization Services, which allows sponsors to significantly reduce the time required to launch and execute high-impact clinical trials.

• Be The Match BioTherapies® Expands Presence In the San Francisco Bay Area For Allogeneic Therapy Development and Commercialization

  10/25/2022

  Be The Match BioTherapies® announced expanded support for clients in the Northern California region.

• Sickle Cell Warrior Program from NMDP/Be The Match Helps Eliminate Barriers to Equitable Care

  9/12/2022

  As part of Sickle Cell Disease Awareness Month in September, The National Marrow Donor Program® /Be The Match® is sharing the Sickle Cell Warrior Program, an initiative designed to eliminate barriers to equitable care, facilitate early referral and typing, and provide resources to empower warriors and caregivers.

• Be The Match BioTherapies® Now Offers A Central Point of Access To Fully-Characterized Cord Blood Units for Commercial and Clinical Use

  8/9/2022

  Be The Match BioTherapies® announced it is now providing cryopreserved Cord Blood Units as allogeneic cell therapy starting material for non-clinical, clinical, and commercial use.

• National Marrow Donor Program®/Be The Match® Awards Amy Strelzer Manasevit Research Program Grant to Dan Peltier, MD, PhD

  2/7/2022

  The National Marrow Donor Program® /Be The Match®, a global leader in cellular therapy, awarded this year's Amy Strelzer Manasevit Research Program grant to Dan Peltier, MD, PhD.

• Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension

  1/6/2022

  Be The Match BioTherapies and Atara Biotherapeutics, Inc., announced an extension of their collaboration to provide high-quality healthy donor cells for Atara’s off-the-shelf T-cell immunotherapy platform for patients with cancer and autoimmune diseases.

• University of Houston Student Yusuf Khan Receives Recognition from Texas Governor Abbott for His Efforts to Increase Awareness of the National Marrow Donor Program/Be The Match

  4/27/2021

  Be The Match Day at the Capitol on April 27 Celebrates Yusuf's Support for HB 780 and the Thousands of Texans Given a Second Chance at Life Through Marrow Transplant

• Be The Match Shares Support For Texas Statewide Bone Marrow Recruitment Program

  3/31/2021

  National Marrow Donor Program/Be The Match®, announced its strong support of Texas Automobile License for Life.

• Georgia General Assembly Proclaims March 4, 2021 "Be The Match Day" To Help Add More Donors on the to Be The Match Registry

  3/3/2021

  For patients battling deadly blood cancers like leukemia or lymphoma or life-threatening blood diseases like sickle cell disease or aplastic anemia, there is a cure.

• National Marrow Donor Program/Be The Match Announce Plan to Launch ACCESS Clinical Trial

  2/25/2021

  The National Marrow Donor Program® /Be The Match® announced plans to launch the ACCESS clinical trial titled A Multicenter Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies.

• National Marrow Donor Program®/Be The Match® and CIBMTR® (Center for International Blood and Marrow Transplant Research®) Note Studies of Older Adults With MDS Demonstrate Significant Survival Benefits of HCT

  12/7/2020

  Initial results from a recent study indicate that for patients between the ages of 50 and 75, overall survival nearly doubled when patients with myelodysplastic syndrome received allogeneic hematopoietic cell transplantation when compared to other treatments.